Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies-Reference-Cited by-同舟云学术

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

Published:2024-04-02 Issue:1 Volume:23 Page:419-431
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Balgos Abundio¹,Hannawi Suad²,Chen Wen-Li³,Abuquta Alaa²,Safeldin Linda²,Hassan Aala²,Alamadi Ahmad²,Tirador Louie⁴,Jaen Anjuli May⁴,Villalobos Ralph Elvi⁵,Mo Chen⁶,Yue Zi-Jing⁶,Ma Ying⁶,Wang Qing-Shuang⁶,Wen Ren-Du⁶,Yao Zheng⁶,Yu Jia-Ping⁶,Yao Wen-Rong⁶,Zhang Jian-Hui⁶,Hong Kun-Xue⁶⁷,Liu Yong⁶⁷,Li Jing-Xin⁷⁸

Affiliation:

1. The Health Centrum, Roxas City, Philippines

2. United Arab Emirates – Al Kuwait-Dubai (ALBaraha) Hospital, Dubai, UAE

3. Department of Rehabilitation Medicine, ZhongDa Hospital, Southeast University, Nanjing, China

4. St. Paul’s Hospital, Iloilo City, Philippines

5. University of the Philippines – Philippine General Hospital, Manila, Philippines

6. Research & Development Department, Jiangsu Recbio Technology Co., Ltd, China

7. School of Public Health, National Vaccine Innovation Platform, Nanjing Medical University, Nanjing, China

8. Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China

Funder

National Natural Science Foundation of China

Jiangsu Provincial Science Fund for Distinguished Young Scholars

Jiangsu Provincial Key Project of Science and Technology Plan

National Science and Technology Major Project

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2024.2334423

Reference24 articles.

1. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

2. World Health Organization. Summary status of COVID-19 vaccines within WHO EUL-PQ evaluation process. 2024 Jan 25. https://www.american-club.com/files/files/WHO_COVID-19_EUL_23-March-2021.pdf

3. World Health Organization. WHO roadmap on uses of COVID-19 vaccines in the context of omicron and high population immunity: an approach to optimize the global impact of COVID-19 vaccines at a time when omicron and its sub-lineages are the dominant circulating variants of concern, based on public health goals, evolving epidemiology, and increasing population-level immunity, irst issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, updated: 21 January 2022, updated: 30 March 2023, latest update: 10 November 2023[M]//WHO roadmap on uses of COVID-19 vaccines in the context of omicron and high population immunity: an approach to optimize the global impact of COVID-19 vaccines at a time when omicron and its sub-lineages are the dominant circulating variants of concern, based on public health goals, evolving epidemiology, and increasing population-level immunity, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, updated: 21 January 2022, updated: 30 March 2023, latest update: 10 November 2023. 2023.

4. Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine

5. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant